Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.
You may also be interested in...
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
While the BCMA-targeting CAR-T competition is grabbing attention, bluebird has good news in sickle cell therapy.